CE-MS in biomarker discovery, validation, and clinical application.
about
Proteomics as a Quality Control Tool of Pharmaceutical Probiotic Bacterial Lysate ProductsProteomic Analysis of Vitreous Humor in Retinal Vein OcclusionClassical MALDI-MS versus CE-based ESI-MS proteomic profiling in urine for clinical applications.Proteomics of vitreous humor of patients with exudative age-related macular degenerationBiomarkers in development of psychotropic drugs.Identification of urinary peptide biomarkers associated with rheumatoid arthritis.Global proteomics and metabolomics in cancer biomarker discovery.Toward rapid, high-sensitivity, volume-constrained biomarker quantification and validation using backscattering interferometryRecent advances in the combination of capillary electrophoresis with mass spectrometry: from element to single-cell analysis.Protein interactome of muscle invasive bladder cancer.Oncoproteomics: Trials and tribulations.Diagnosis and Prediction of CKD Progression by Assessment of Urinary PeptidesIdentification of Symptomatic Fetuses Infected with Cytomegalovirus Using Amniotic Fluid Peptide BiomarkersMass spectrometry for diabetic nephropathy monitoring: new effective tools for physicians.Urinary proteomic profiling in severe obesity and obstructive sleep apnoea with CPAP treatment.The use of urinary proteomics in the assessment of suitability of mouse models for ageing.Pancreatic preneoplastic lesions plasma signatures and biomarkers based on proteome profiling of mouse models.Ultrasensitive sample quantitation via selected reaction monitoring using CITP/CZE-ESI-triple quadrupole MS.Identification of ageing-associated naturally occurring peptides in human urineCapillary zone electrophoresis for bottom-up analysis of complex proteomesClinical application of urinary proteomics/peptidomics.Recent developments in CE and CEC of peptides (2009-2011).Recent advances in the application of capillary electromigration methods for food analysis and Foodomics.Recent advances in the application of CE to forensic sciences, an update over years 2009-2011.Capillary electrophoresis/mass spectrometry relevant to pharmaceutical and biotechnological applications.On-line CE/ESI/MS interfacing: recent developments and applications in proteomics.Potential biomarkers for early detection of acute graft-versus-host disease.Recent advances in capillary electrophoresis coupled to mass spectrometry for clinical proteomic applications.Clinical applications of capillary electrophoresis coupled to mass spectrometry in biomarker discovery: Focus on Bladder Cancer.Recent developments in capillary and microchip electroseparations of peptides (2011-2013).Review of the CE-MS platform as a powerful alternative to conventional couplings in bio-omics and target-based applications.Proteomic urinary biomarker approach in renal disease: from discovery to implementation.Capillary zone electrophoresis on-line coupled to mass spectrometry: A perspective application for clinical proteomics.CE-MS-based proteomics in biomarker discovery and clinical application.New perspectives on bioactivity of olive oil: evidence from animal models, human interventions and the use of urinary proteomic biomarkers.Recent progress in urinary proteome analysis for prostate cancer diagnosis and management.BcCluster: A Bladder Cancer Database at the Molecular Level.Comparison of higher energy collisional dissociation and collision-induced dissociation MS/MS sequencing methods for identification of naturally occurring peptides in human urine.Urinary proteomics in obstructive sleep apnoea and obesity.Untargeted Screening of Urinary Peptides Using Offline Nano-Liquid Chromatography: MALDI-TOF/TOF Mass Spectrometry.
P2860
Q28533986-BBA86B6D-4F93-4056-B131-640817030B3DQ28552292-D4B029E0-BE56-47E4-A701-F5D5B5282313Q31148183-8B9D3B82-5BD6-42E2-B50D-9D15B4688DDCQ33610106-ABEDC9E5-90D8-422A-BC83-2DB73085E009Q33993209-09222A4C-A011-4861-AB64-55347CCF1AC0Q34075303-EF4FD1DD-DFE2-4EC7-B781-91F71F3ED2C2Q34079038-6DB1867D-7DCB-478B-B22E-8292552588E5Q34434036-5A8338C9-7CAB-407D-89CF-D93A9658CFECQ34480649-EEB3BE69-2048-4465-BB8B-C324A778399FQ34876528-53447053-7C90-4B9C-A126-87C66EFC4B0DQ35827653-6A83CEA9-10E1-44D4-8BF7-EDCBD597C9ECQ35903097-CFCD2CA9-5A44-4252-8C63-62E44AEAAB1CQ35903895-0A8D7992-0015-4D66-BD6C-80BBD7392698Q35997377-01D82648-3619-43D7-83E6-985B5F42AC0BQ36171255-54D33CCE-4B48-443C-B4CD-416ECF64EE79Q36281053-3F0177B4-CE9F-41AC-BE73-D313E2CD7589Q36443870-5919D55C-E748-4F66-95F2-11F95F96112AQ36540986-E54F1189-C9A7-4717-9091-72DE0796B8F9Q36544030-0A748D01-4B0D-47CD-AE5A-9722324BB2B2Q36630922-15B202CD-F1BB-4466-B74B-976E30F0FC4FQ37945790-F0EB49D6-79A7-4295-B7B4-AC99D6536FBEQ37964561-CE8C5720-9973-463D-ACED-D8DD9A4FB648Q37965420-F698D7EE-4807-45AC-92F4-C196E2C491D5Q37972860-9E1A3244-B1A1-4490-9BD9-0498CB4D5A86Q38021959-1E6F2824-8500-4CDF-8EF9-4599BF132C4CQ38034203-AFA5FB08-B70E-418C-90F8-0089DE9F0705Q38038568-115DE456-B9DC-44EE-B65E-E667535CB9C6Q38091336-A4B01223-FE99-4786-8319-72D460F24D53Q38130892-A75B2C9A-E901-4D33-AC92-F14DEFED4AAFQ38164318-6F4E0E9D-6656-40D0-9636-A086DB3A4CC4Q38184491-77012535-0F7C-4ED4-8CC9-6FAB48F61F15Q38196316-C4EFA0A0-13D8-4DE3-866C-47BA57BBEF58Q38340351-94DA7EB1-0524-4093-99F4-A0B22F16D706Q38340358-56F820BC-60B6-47F0-B840-63189A0F91E5Q38549466-CC4D7E36-508F-4CAA-BCF9-FF0412754174Q38613772-720C3119-F71E-4524-8989-229719274AA0Q39634042-9516E7E7-A453-4887-A32A-B73586E17205Q41142978-EDA3BC23-2AF1-4F10-8ACF-AE205ADD5B90Q48026870-856333E4-A408-4E0A-810A-F9C003EA6050Q50078073-5F988AD6-F476-43F8-8B04-2F64382769A5
P2860
CE-MS in biomarker discovery, validation, and clinical application.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
CE-MS in biomarker discovery, validation, and clinical application.
@en
CE-MS in biomarker discovery, validation, and clinical application.
@nl
type
label
CE-MS in biomarker discovery, validation, and clinical application.
@en
CE-MS in biomarker discovery, validation, and clinical application.
@nl
prefLabel
CE-MS in biomarker discovery, validation, and clinical application.
@en
CE-MS in biomarker discovery, validation, and clinical application.
@nl
P2860
P356
P1476
CE-MS in biomarker discovery, validation, and clinical application.
@en
P2860
P356
10.1002/PRCA.201000058
P577
2010-11-11T00:00:00Z